Llorca P M, Penault F, Lançon C, Dufumier E, Vaiva G
CH Sainte-Marie, Clermont-Ferrand.
Encephale. 1999 Nov-Dec;25(6):638-44.
Neuroleptics are the main biological treatment for psychotic patients. The brutal withdrawal of a neuroleptic treatment may induce an important aggravation of the psychotic symptoms. A few of those relapses may occur very early after the interruption of treatment; they are often associated with a modification of the symptoms and an unfavorable evolution in the course of the illness. Using those clinical observations a few authors have developed the concept of supersensitivity psychosis to explain those kinds of relapses and to formulate hypothesis about tolerance and resistance to neuroleptics. They focus on the possible correlation between supersensitivity psychosis and tardive dyskinesia. We report three cases of a dramatic aggravation of the psychotic symptomatology following the withdrawal of clozapine in three schizophrenic patients resistant to classical neuroleptic treatment. According to the clinical data and to the physiopathological hypothesis, the concept of supersensitivity psychosis can have implications in the therapeutic management of resistant schizophrenic patients.
抗精神病药物是治疗精神病患者的主要生物疗法。突然停用抗精神病药物治疗可能会导致精神病症状显著加重。其中一些复发可能在治疗中断后很早就出现；它们通常与症状改变以及疾病进程中的不良演变有关。基于这些临床观察，一些作者提出了超敏性精神病的概念，以解释这类复发情况，并就对抗精神病药物的耐受性和耐药性提出假设。他们关注超敏性精神病与迟发性运动障碍之间可能存在的关联。我们报告了3例对经典抗精神病药物治疗耐药的精神分裂症患者停用氯氮平后精神病症状急剧加重的病例。根据临床数据和生理病理假设，超敏性精神病的概念可能会对耐药性精神分裂症患者的治疗管理产生影响。
